We Work For Health

Because of the Biosimilar Red Tape Elimination Act, an overwhelming majority of physicians are concerned about patient health and safety. Congress must maintain rigorous standards for #biosimilar interchangeability, as this Altoona Mirror op-ed explains:

Congress is considering a bill that could exacerbate government waste and give American companies' most valuable trade secrets to China. Read more on the problematic Medication Affordability and Patent Integrity Act in RealClear Media Group:

IP protections help scientists and #biopharma leaders quickly and effectively address global health challenges, including pandemics and rare diseases. That's one of our Executive Director Dan Leonard's top-10 reasons to #ProtectPatents. https://lnkd.in/eZaCw5Kj

An undesirable interaction between two well-intended #IRA provisions may result in reduced access and/or higher out-of-pocket drug costs for many Medicare beneficiaries, particularly for those in underserved populations. Read more in RealClearHealth: https://lnkd.in/d-rFnbSY

NEW REPORT: IQVIA published research today that provides critical context to government claims of so-called drug savings through the #IRA and explores the law's true impact on patient costs. The findings confirm IRA #Medicare drug price controls will not achieve their stated goal of consistently reducing patient expenses. In fact, some people may pay more. To learn more, check out... IQVIA's full report: https://lnkd.in/erjkyjYM Our new blog: https://lnkd.in/eNbB6Dq2 Our report fact sheet: https://lnkd.in/eQ_zzeNF

Incubate Coalition's "Small Molecules, Big Voices" video series gathers life sciences leaders to discuss why investing in small molecule R&D is essential for continuing to deliver cutting-edge therapies to patients in need. Watch here:

Hudson Institute's webinar today covered the state of play concerning empirical evidence on the connection between drug patents and drug prices and whether officials are truly engaging in evidence-based policymaking. Panelists' insights included… Novartis VP/Global Head of IP Affairs Corey Salsberg: "With complex technology, you can expect to have more patents because it requires more innovation." He noted the iPad tablet being a compilation of many inventions — and medical tablets often requiring the same. University of Missouri-Columbia, School of Law professor Erika Lietzan recognized "it's only been in the last decade or so that we've started to see attacks on drug innovation that are grounded in big data sets" so it's important for experts to "set the record straight" when policymakers are shown flawed reports. Hudson’s Adam Mossoff warned "unreliable, unconfirmed numbers that cannot be replicated" should not be analyzed for patent/innovation policy: "Counting patents is not a metric for innovation because what matters is what the patents do and what the patents are covering." Watch a full replay of the panel discussion here: https://lnkd.in/eSrGnAv8

No matter how favorable a state’s innovation landscape, misguided federal policies like the Medication Affordability and Patent Integrity Act can undermine even the most fertile ecosystem. Read Deseret News for BioUtah's local example:

Check out this alarming analysis from Avalere: Physicians could lose at least $25 billion in add-on payments for 10 Part B drugs expected to be negotiated by CMS under the #IRA, with oncology products accounting for at least $12 billion.

From exclusive rights to innovate and then affordable generic alternatives over the #IP lifecycle, #patentprotections ensure investors, scientists, and patients all meet their needs. Learn more from our Executive Director Dan Leonard's blog: https://lnkd.in/eZaCw5Kj